The biotechnology company's lead product candidate is ibrexafungerp (formerly known as SCY-078), an IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections
SCYNEXIS reveals positive interim data from its Phase 3 FURI study
Quick facts: SCYNEXIS, Inc.
Market Cap: $64.06 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE